Usefulness of the antisense and triplex anti-IGF-1 techniques for postoperative cellular gene therapy of malignant gliomas expressing IGF-1;Pooperacyjna terapia genokomórkowa z ekspresja IGF-1 glejaka wielopostaciowego przy zastosowaniu techniki antysensu i tripleksu anty-IGF-1

Neurologia i Neurochirurgia Polska

Volumn 40, Issue 6, 2006, Pages 509-515

  Kosprzak, Heliodor A ^a,c   Trojan, Jerzy ^a   Bierwagen, Maciej ^a   Kopiński, Piotr ^a   Jarocki, Piotr ^b   Bartczak, Karina ^a   Czapiewska, Joanna ^a  

^a Katedra i Zak ad Genoterapii   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c NONE   (Poland)

Author keywords

Gene therapy; Glioblastoma; IGF 1

Indexed keywords

CANCER VACCINE; DEXAMETHASONE; OLIGONUCLEOTIDE; SOMATOMEDIN BINDING PROTEIN 1; TEMOZOLOMIDE;

ADOLESCENT; ADULT; AGED; ANTISENSE THERAPY; ANTISENSE VECTOR; ARTICLE; CANCER CELL; CANCER IMMUNIZATION; CANCER SURGERY; CELL BASED GENE THERAPY; CELL CULTURE; DRUG FORMULATION; DRUG STRUCTURE; FEMALE; GENE EXPRESSION; GENETIC TRANSFECTION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOCYTE SUBPOPULATION; MALE; MULTIPLE CYCLE TREATMENT; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR LOCALIZATION;

EID: 33846212641     PISSN: 00283843     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Guo Y., Wu M., Chen H. i wsp. Effective tumor vaccine generated by fusion of hepatoma cells with lymphocytes B cells. Science 1994; 263: 518-520.
2. Apuzzo M.L., Mitchell M.S. Immunological aspects of intrinsic glial tumors. J Neurosurg 1981; 55: 1-18.
3. Ly A., Francois J.C., Lia C. i wsp. Alterations in tumorigenicity of embryonal carcinoma cells by IGF-1 triple helix induced changes in immunogenicity and apoptosis. Life Sci 2000; 68: 307-319.
4. Lia C., Upegui-Gonzalez L., Francois J.C. i wsp. Use of the IGF-1 antisense strategy in the treatment of the hepatocarcinoma. W: Walden i wsp. [red.]. Gene Therapy of Cancer. Plenum Press, New York 1998, s. 35.
5. Wysocki P.J., Karczewska A., Mackiewicz A. Gene modified tumor vaccines in therapy of malignant melanoma. Otolaryngol Pol 2002; 56: 147-153.
6. Trojan J., Blossey B.K., Johnson T.R. i wsp. Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I. Proc Natl Acad Sci USA 1992; 89: 4874-4878.
7. Trojan L.A., Kopinski P., Wei M.X. i wsp. IGF-I: from diagnostic to triple-helix gene therapy of solid tumors. Acta Biochim Pol 2002; 49: 979-990.
8. Szpechcinski A, Trzos R, Jarocki P i wsp. Presence of MHC-I in rat glioma cells expressing antisense IGF-I-receptor RNA. Ann Acad Med Bial 2004; 49 (supl. 1): 98-104.
9. Upegui-Gonzalez L.C., Ly WSP, Sierzega M. i wsp. IGF-I triple helix strategy in hepatoma treatment. Hepatogastroenterology 2001; 48: 656-662.
10. Ly A., François J.C., Duc H.T. i wsp. IGF-I triple helix technology changes tumorigenicity of embryonal carcinoma cells by immune and apoptotic effects. Life Sci 2000; 68: 307-309.
11. Trojan L.A., Kopinski P., Mazurek A. i wsp. IGF-1 triple helix gene therapy of rat et human gliomas. Ann Acad Med Bial 2003; 48: 18-27.
12. Trojan J., Duc H., Upegui-Gonzalez L. i wsp. Presence of MHC-1 and B-7 molecules in rat and human glioma cells expressing antisense IGF-1 mRNA. Neurosci Lett 1996; 212: 9-12.
13. Baserga R., Resnicoff M., D'Ambrosio C. i wsp. The role of the IGF-I receptor in apoptosis. Vitam Horm 1997; 53: 65-98.
14. Kasprzak H.A., Bierwagen M., Śniegocki M. Wpływ zastosowania genoterapii na biologie reoperowanych niedojrzałych glejaków wielopostaciowych. Neuml Neurochir Pol 2004; 38 (supl. 2): S100.